On September 15, GENSCRIPT BIO fell 3.88% in regular trading, trading at HK$32.68 per share, with turnover of approximately HK$139 million. The decline coincided with the settlement date for the company's recently announced share placement.

The company previously disclosed a placement of 77.126 million new shares at HK$30.50 each, representing a discount of approximately 4.7% to the prior closing price, with net proceeds of approximately HK$2.327 billion. Citigroup and J.P. Morgan acted as placement agents, with the expected delivery date on or before September 15. As newly placed shares officially entered circulation on the settlement date, the short-term dilution effect and the anchoring of market price toward the placement price weighed on the stock. Following the placement, major shareholder GenScript Corporation's stake was diluted from 36.32% to 35.09%.

Approximately 70% of the net proceeds are earmarked for expanding the group's AI-driven drug discovery (AIDD) platform capacity and infrastructure, 20% for related R&D and global business development, and 10% for general corporate purposes. J.P. Morgan previously maintained an Overweight rating with a target price of HK$41, citing sustained AIDD order momentum and improving capacity utilization.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)